We are beginning to understand the biological basis of aging and age-related diseases, making the discovery of new therapies actionable for the first time. This is a promising new area in science with potential for meaningful impact on human healthspan, the period of a person's life during which they are generally healthy and free from serious or chronic illness. The benefits emerging from anti-aging science have enormous potential for the treatment of age-related conditions, such as cardiometabolic and kidney diseases, osteoarthritis, immunosenescence, and neurodegeneration. The mechanistic target of rapamycin (mTOR) and cellular senescence are two fields of scientific discovery being pursued as domains for new drug development. Panelists are leaders at the companies translating these findings into new pharmacological interventions that impact these core biological aging mechanisms, which are increasingly recognized as catalysts for a wide range of poorly treated prevalent diseases.
Ability Level: All
Session ID: 503689